What worked, what didn't, and the papers behind it.
A decade of field notes from inside hypermobile Ehlers-Danlos syndrome, mast cell activation syndrome, and the regenerative-medicine pathways that touch them. Written by one patient — me — with primary-source rigor. Not medical advice.
Start here
-
April 28, 2025
Two Resets: Stellate Ganglion Blocks and the Hoffman Process
Two upstream resets — Neuro-Reset with bilateral stellate blocks and vagus hydrodissection, and the Hoffman Process — that finally made the regenerative work stick after years of cycling back into flares.
-
February 22, 2025
Anterior Pannus in PICL and CCI: What Patients and Physicians Should Actually Worry About
An evolving question in craniocervical instability: does anterior pannus rule out PICL? A real case, the conflicting reads, and what Henderson and Centeno actually say about it.
-
February 15, 2025
Managing hEDS and MCAS, Step by Step
A decade of trial and error compressed into a working protocol — diagnostics, injury sequencing, mast cell control, hormones, and the specific physicians who actually understand the overlap.
-
February 10, 2025
From Disability to Strength: A Decade Inside hEDS, MCAS, and Regenerative Medicine
The personal case study underneath every other post on this site — what hEDS and MCAS did to my body, what surgeries and regenerative work undid, and the specific genetic and biochemical levers that mattered.
Recent
-
July 27, 2025
Inflammaging, Longevity, and the Unknowns of Exosome Therapy: A Cautionary View
Inflammaging is a driver of age-related disease, not just a symptom. Exosomes may help, but in a largely unregulated market the variability between batches — even from the same source tissue — makes caution non-optional.
-
June 18, 2025
Botox: A Closer Look at Its Use, Risks, and the Importance of Patient Screening
Fifteen years of ~20 units every 4–6 months, then I stopped — hip abduction nearly doubled from 90–100 lbs to 180 lbs and I pulled up unassisted for the first time. The Alzheimer's link is my working hypothesis, not established fact. The strength data is mine.
-
April 28, 2025
Two Resets: Stellate Ganglion Blocks and the Hoffman Process
Two upstream resets — Neuro-Reset with bilateral stellate blocks and vagus hydrodissection, and the Hoffman Process — that finally made the regenerative work stick after years of cycling back into flares.
-
April 26, 2025
Lessons from Seven Years Inside hEDS, MCAS, POTS, and Dysautonomia
After seven years of trial, error, and rebuilding, these are the interventions that moved me from bedbound to functional: stellate ganglion blocks, environmental detox, slow tendon loading, osteopathic care paired with regenerative medicine, and a multi-year timeline.
-
March 10, 2025
When Exosome Therapy Goes Wrong
Three real cases of serious complications from IV exosome therapy — cancer recurrence, DVT, systemic inflammation — plus what I've learned about source verification, batch characterization, and why microneedling is a very different risk profile than IV.
-
February 22, 2025
Anterior Pannus in PICL and CCI: What Patients and Physicians Should Actually Worry About
An evolving question in craniocervical instability: does anterior pannus rule out PICL? A real case, the conflicting reads, and what Henderson and Centeno actually say about it.
-
February 15, 2025
Managing hEDS and MCAS, Step by Step
A decade of trial and error compressed into a working protocol — diagnostics, injury sequencing, mast cell control, hormones, and the specific physicians who actually understand the overlap.
-
February 10, 2025
From Disability to Strength: A Decade Inside hEDS, MCAS, and Regenerative Medicine
The personal case study underneath every other post on this site — what hEDS and MCAS did to my body, what surgeries and regenerative work undid, and the specific genetic and biochemical levers that mattered.
-
February 5, 2025
FDA Stem Cell & Exosome Therapy Crackdown: What It Means for Regenerative Medicine
The FDA issued warning letters to Chara Biologics, INCELL, Neobiosis, and Platinum Biologics for cGMP violations and unapproved biologic manufacturing — reframing perinatal-derived products as biologic drugs rather than tissue allografts.
-
February 5, 2025
Muse Stem Cells: Hype, Science, and Regenerative Medicine
My February 2025 take on Muse cells. I no longer hold this view — after a year reading the primary literature, my position has changed. The original post is preserved below, unedited.